Authors

Latest:

Dr Bahadur on the Shift in Frontline CDK4/6 Inhibitor Selection in HR+/ HER2– Breast Cancer Breast Cancer

Shakeela Bahadur, MD, discusses how recent data have informed the selection of approved CDK4/6 inhibitors in the frontline setting for patients with metastatic hormone receptor–positive, HER2-negative breast cancer.

Sajeve Samuel Thomas, MD

Latest:

Dr. Thomas on the Safety Profile of Lifileucel Plus Pembrolizumab in Advanced Melanoma

Sajeve Samuel Thomas, MD, discusses the safety profile of lifileucel plus pembrolizumab in advanced melanoma.

Rachna Shroff, MD, MS, FASCO

Latest:

Triplet Chemo Trial Raises Importance of Accurately Defined Subgroups in Biliary Tract Cancer Research: With Rachna Shroff, MD, MS, FASCO

Dr Shroff discusses the SWOG S1815 trial of nab-paclitaxel plus gemcitabine and cisplatin in patients with newly diagnosed, advanced biliary tract cancer.

Christopher Su, MD, MPH

Latest:

5 Tips for a First-Year Fellow

Christopher Su, MD, MPH, highlights 5 tips for first-year oncology fellows.

Rachel Zeig-Owens, DRPH

Latest:

The Importance of Lung Cancer Screening in Individuals Exposed to the World Trade Center Disaster

Investigators evaluated risk factor–based guidelines and risk model–based strategies for lung cancer screening in World Trade Center–exposed responders.

Randy W. Crim, MD, FACS, FASCRS

Latest:

Transforming Cancer Care Through Data: How Texas Colon & Rectal Specialists Enhances Outcomes, Experiences, and Efficiency

How Texas Colon & Rectal Specialists enhance outcomes, experiences, and efficiency data-driven care to improve patient outcome.

Michael A. Davies, MD, PhD

Latest:

Dr. Davies on the Potential Utility of ERK Inhibitors in Melanoma

Michael A. Davies, MD, PhD, discusses the potential utility of ERK inhibitors in melanoma.

Vignesh Packiam, MD

Latest:

Dr. Packiam on Safety of Cabazitaxel/Gemcitabine Plus Pembrolizumab in Urothelial Carcinoma

Vignesh Packiam, MD, discusses the adverse effects associated with cabazitaxel and gemcitabine with pembrolizumab in patients who are unresponsive to docetaxel with non-muscle invasive urothelial carcinoma.

Siddartha Yadav, MD, FACP

Latest:

Contralateral Breast Cancer Treatment With Germline Mutation Carriers

Siddartha Yadav, MD, FACP, of Mayo Clinic, discusses personalizing treatment for patients with germline–mutant contralateral breast cancer.

Rebecca C. Arend, MD, MPH

Latest:

Optimizing Therapy for MMR-Proficient Endometrial Cancer

Panelists discuss how the DUO trial demonstrates the benefit of durvalumab in adjuvant endometrial cancer treatment and suggests potential value of adding olaparib in specific subgroups like mismatch repair–proficient patients, though emphasizing the need for confirmatory studies before routine clinical implementation.

Susan Hays, ANP, Washington University Siteman Cancer Center

Latest:

“Breast Cancer Talk”: Nursing Perspectives on HER2-Targeted Agents in Breast Cancer

Mark Leick, MD

Latest:

Dr Leick on Limitations Associated With CAR T-Cell Therapy in Hematologic Malignancies

Mark Leick, MD, discusses the challenges and limitations associated with the use of CAR T-cell therapy across hematologic malignancies, highlighting how ongoing research may potentially ameliorate present unmet needs.

Ann-Kathrin Eisfeld, MD

Latest:

Dr Eisfeld on Timing of Molecular Testing and the Start of Treatment in AML

Ann-Kathrin Eisfeld, MD, discusses factors to consider when deciding whether to start treatment right away or wait for molecular testing results in patients with acute myeloid leukemia.

Jennifer L. Atlas, MD

Latest:

Metastasis Patterns of Basal Cell Carcinoma

A look at how common metastatic basal cell carcinoma is in clinical practice and when to consider frontline immunotherapy.

Alexandra E. Lynch, PA

Latest:

Looking Ahead to the Future of CAR T Therapy for B-Cell Lymphoma

Panelists discuss how CAR T therapy represents the best curative option for relapsed B-cell lymphoma and how community oncologists must prepare for the inevitable expansion of cellular therapies across multiple disease areas.

Daniel W. Lin, MD

Latest:

Dr. Lin on the Limitations of Current Biomarkers in Prostate Cancer

Daniel W. Lin, MD, discusses the limitations of currently available biomarkers in prostate cancer.

Anirban P. Mitra, MD, PhD

Latest:

Dr. Mitra on Nadofaragene Firadenovec Plus Anti–PD-1 Therapy in BCG-Unresponsive NMIBC

Anirban P. Mitra, MD, PhD, discusses data from an assessment of PD-1 and PD-L1 status on transurethral resection specimens collected from patients with non–muscle-invasive bladder cancer who received nadofaragene firadenovec as part of a phase 3 trial.

Cristiane Bergerot PhD, MS, BS

Latest:

Dr. Bergerot on Improved HRQoL With a Higher Starting Dose of Lenvatinib Plus Everolimus in RCC

Cristiane Bergerot PhD, MS, BS, discusses how a higher starting dose of lenvatinib, to be combined with everolimus, can improve health-related quality of life in patients with renal cell carcinoma, as demonstrated in a phase 2 open-label trial.

Nathan L. Avaritt, PhD

Latest:

Molecular Approaches May Increase Responsiveness to Immunotherapy for Patients With Metastatic Melanoma

The recent development of therapeutics which stimulate immune response to tumor cells has revolutionized the treatment landscape for cutaneous melanoma.

Shun Lu, MD, PhD

Latest:

EGFR+ Advanced NSCLC Resistant to Frontline TKIs: C797S Mutation

Expert perspectives on the management of C797S-mutated non–small cell lung cancer following failure of frontline TKIs.